Abstract Library

#3885 Adaptive immunosuppressive resistance mechanisms towards antiangiogenic immunotherapies revealed in a pancreatic neuroendocrine tumor (PNET) model

Introduction: Pancreatic neuroendocrine tumors (PNETs) are mostly indolent but can achieve malignancy. Surgery is the only approved first-line therapy. Kinase inhibitors and radiotherapy for unresectable PNETs are non-curative and targeted therapies are currently lacking for PNETs. However, immune checkpoint inhibitors have created a paradigm shift in cancer therapy with significant increase in overall survival, but are curative only in a subset of patients, partly due to limited T cell infiltration, especially in angiogenic and cold tumors like PNETs. Parallelly, antiangiogenic therapy increases lymphocyte infiltration by normalising the tumor vasculature. Tallying antiangiogenic to immunotherapies (AI) has provided improved survival benefits for patients of advanced RCCs and HCCs, while other cancers like glioblastoma remain highly resistant.

Conference:

Presenting Author:

Authors: John Robbert D, Guyot M, Killian T, Verslype C, Lambrechts D,

Keywords: Pancreatic neuroendocrine tumor, Antiangiogenic immunotherapy, single cell transcriptomics, Immunosuppression,

#3757 Subtype-specific landscape of splicing-associated neoantigens and mutations in pancreatic neuroendocrine tumors

Introduction: In pancreatic neuroendocrine tumors (PanNETs), there has recently been advancement in understanding the heterogeneity (metastases-like primary; MLP-1/2, intermediate, and insulinoma subtypes) and immunological landscapes. Immunotherapies provide modest therapeutic benefits to patients, which may be linked to low mutational neoantigen loads in PanNETs.

Conference:

Presenting Author: Sadanandam A

Authors: Sadanandam A, Lawlor R, Larkeryd A, Mahalingam A, Mafficini A,

Keywords: Pancreatic neuroendocrine tumor, isoform switching, subtype, mutation, neoantigens, splice variant, spliceosomal mutation, immunotherapy, immunosuppression,

#3330 Effects of transplantation related immunosuppression on co-existent neuroendocrine tumors

Introduction: Here we detail our experience of managing patients found with NETs whilst on immunosuppression for a transplanted organ or receiving an organ from a donor with a NET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Shah H

Authors: Shah H, Faulkes R, Shetty S, Shah T,

Keywords: neuroendocrine tumor, immunosuppression, transplantation,

#1536 Merkel Cell Carcinoma – Epidemiology Data from the Czech National Cancer Registry

Introduction: Merkel cell carcinoma (MCC) is rare and aggressive neuroendocrine tumor. The incidence is increasing worldwide, most probably due to population aging (mostly in the Western Europe), higher rates of sun exposure, immunosuppression and other not well defined epigenetic changes.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Bajciova V

Authors: Bajciova V, Barkmanová J, Zvolsky M, Sedlackova E,

Keywords: Merkel cell carcinoma, register, epidemiology, ,

#1113 A Novel Approach for a Metastatic Gut-Derived Neuroendocrine Tumour: Simultaenous Intestinal and Vascularised Sentinel Forearm Flap Transplantation

Introduction: Non-resectable tumours involving the mesenteric root are an indication for intestinal and multivisceral transplantation (MVT). Vascularised sentinel forearm flaps (VSFF) offer possibilities for monitoring graft rejection and tailoring immunosuppression (IS) regimens.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Frilling A

Authors: Clift A, Giele H, Vrakas G, Reddy S, Macedo R,

Keywords: neuroendocrine, tumor, transplantation,